Ambrx Biopharma Price to Free Cash Flow Ratio 2020-2021 | AMAM

Historical price to free cash flow ratio values for Ambrx Biopharma (AMAM) since 2020. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Ambrx Biopharma Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-12-06 8.11 inf
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.322B $0.014B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71